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Background: The impact of appropriate use criteria (AUC) for myocardial perfusion imaging (MPI) on lifetime attributable risk (LAR) of cancer and 
the clinical benefit-to-LAR ratio is unknown.
Methods: In a cohort of 1511 consecutive patients who underwent clinically indicated Tc99m MIBI MPI we determined adherence to the AUC. 
Patients were prospectively followed for 27 ± 10 months for MACE (cardiac death or myocardial infarction) and revascularization (REV) within 6 
months of MPI. Multivariate logistic regression models were used to determine the annualized predicted probability of MACE and 6-month REV for 
each patient, accounting for significant clinical and imaging covariates (Table). We determined the effective radiation dose and LAR for each subject. 
The benefit-to-risk ratios, for each patient, were calculated for predicted annual MACE and 6-months REV rates to LAR.
results: Patients with inappropriate MPI were more likely to be younger, women, at lower clinical risk and have a normal MPI (Table). Although 
radioisotope and effective doses received are similar between the study groups, those with inappropriate MPI had significantly higher LAR and 
profoundly lower benefit-to-risk ratios (Table). In the inappropriate use group, women had greater LAR and profoundly lower benefit-to-risk ratios 
than men (P < 0.03).
conclusion: Inappropriate MPI use is associated with, not only unnecessary, but excess radiation risk and lower benefit-to-risk ratio; this is 
particularly profound among women.
Inappropriate
n=688 (45.5%)
Appropriate/Uncertain
n=823 (54.5%) P value
Clinical 
Age (yrs) 53±12 63±11 <0.001
Women 399 (58.0%) 258 (31.3%) <0.001
Framingham 10-yr CHD Risk (%) 8±6 17±11 <0.001
Coronary artery disease prevalence*(%) 5±3 22±12 <0.001
Known coronary artery disease 24 (3.5%) 140 (17.0%) <0.001
Exercise stress 610 (88.7%) 554 (67.3%) <0.001
MPI
Abnormal MPI (SSS > 3) 48 (7.0%) 119 (14.5%) <0.001
Ischemia (SDS > 1) 41 (6.0%) 81 (9.8%) 0.006
Post-stress ejection fraction < 50% 25 (3.6%) 53 (6.4%) 0.01
Outcomes
MACE (Cardiac death or MI) 2 (0.3%) 20 (2.4%) <0.001
REV within 6 months rate 10 (1.5%) 19 (2.3%) 0.23
Predicted Probability Annual MACE (%) 0.36 ± 1.22 0.88 ± 2.22 <0.001
Predicted 6 months REV (%) 1.39 ± 4.60 2.36 ± 6.45 0.001
Radiation / LAR 
Total (rest + stress) 99mTc dose (mCi) 44.6 ± 3.5 44.5 ± 3.3 0.81
Effective absorbed dose (mSv) 13.6 ± 1.2 13.5 ± 13.5 0.43
LAR of cancer (%) 0.08 ± 0.03 0.06 ± 0.02 <0.001
Benefit to Risk Ratio
Predicted MACE to LAR ratio 10.7 ± 74.7 27.0 ± 92.4 <0.001
REV 6 months to LAR ratio 21.7 ± 65.6 50.4 ± 146.0 <0.001
CHD: coronary heart disease; CAD: coronary artery disease; MPI: myocardial perfusion imaging; MACE: major adverse cardiac events; MI: myocardial infarction; LAR: lifetime 
attributable risk of cancer related to radioisotope; REV: revascularization. *Based on Diamond and Forrester tables in patients with chest pain or ischemic equivalent.The predicted 
probabilities of annual MACE rate and 6-months revascularization were adjusted for age, gender, CAD risk factors, CAD status, cardio-protective medication use, and MPI outcome 
predictors (SSS, EF and TID for MACE and SDS for revascularization).
